CO2020000227A2 - Moduladores de nlrp3 - Google Patents
Moduladores de nlrp3Info
- Publication number
- CO2020000227A2 CO2020000227A2 CONC2020/0000227A CO2020000227A CO2020000227A2 CO 2020000227 A2 CO2020000227 A2 CO 2020000227A2 CO 2020000227 A CO2020000227 A CO 2020000227A CO 2020000227 A2 CO2020000227 A2 CO 2020000227A2
- Authority
- CO
- Colombia
- Prior art keywords
- nlrp3
- modulators
- nlrp3 modulators
- compounds
- variables
- Prior art date
Links
- 101150061038 NLRP3 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Amplifiers (AREA)
- Burglar Alarm Systems (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532932P | 2017-07-14 | 2017-07-14 | |
| US201862662405P | 2018-04-25 | 2018-04-25 | |
| US201862689412P | 2018-06-25 | 2018-06-25 | |
| PCT/US2018/041723 WO2019014402A1 (en) | 2017-07-14 | 2018-07-12 | MODULATORS OF NLRP3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020000227A2 true CO2020000227A2 (es) | 2020-01-17 |
Family
ID=63036509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0000227A CO2020000227A2 (es) | 2017-07-14 | 2020-01-10 | Moduladores de nlrp3 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11344543B2 (enExample) |
| EP (1) | EP3652166B1 (enExample) |
| JP (1) | JP7159282B2 (enExample) |
| KR (1) | KR102698385B1 (enExample) |
| CN (2) | CN110914258A (enExample) |
| AU (1) | AU2018301681B2 (enExample) |
| BR (1) | BR112020000523A2 (enExample) |
| CA (1) | CA3069524A1 (enExample) |
| CL (1) | CL2020000085A1 (enExample) |
| CO (1) | CO2020000227A2 (enExample) |
| ES (1) | ES3002968T3 (enExample) |
| IL (1) | IL271935A (enExample) |
| MY (1) | MY201080A (enExample) |
| NZ (1) | NZ761519A (enExample) |
| PE (1) | PE20200296A1 (enExample) |
| SG (1) | SG11202000248UA (enExample) |
| TW (1) | TWI791556B (enExample) |
| WO (1) | WO2019014402A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ769136A (en) | 2018-04-25 | 2024-04-26 | Innate Tumor Immunity Inc | Nlrp3 modulators |
| US12338228B2 (en) * | 2019-01-14 | 2025-06-24 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| ES2930151T3 (es) * | 2019-01-14 | 2022-12-07 | Innate Tumor Immunity Inc | Moduladores heterocíclicos de NLRP3, para su uso en el tratamiento del cáncer |
| KR102865929B1 (ko) * | 2019-01-14 | 2025-09-29 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| US20220056043A1 (en) | 2019-02-19 | 2022-02-24 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| WO2021114691A1 (zh) * | 2019-12-13 | 2021-06-17 | 四川科伦博泰生物医药股份有限公司 | 含氮并环化合物、其制备方法及用途 |
| AU2020446002A1 (en) | 2020-04-29 | 2022-12-22 | Shanghai Ringene Biopharma Co., Ltd. | Benzothiazolyl biaryl compound, and preparation method and use |
| CN115362155B (zh) * | 2020-07-22 | 2024-06-18 | 中国医药研究开发中心有限公司 | 芳胺类衍生物及其制备方法和医药用途 |
| KR102409345B1 (ko) * | 2020-09-22 | 2022-06-16 | 가톨릭대학교 산학협력단 | Nlrp3 인플라마좀 억제제 및 이의 용도 |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4075343A (en) * | 1976-09-13 | 1978-02-21 | Pfizer Inc. | Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof |
| JPS5390271A (en) | 1977-01-14 | 1978-08-08 | Pfizer | Method of producing 22aminoo44hydroxyquinoline |
| US4175193A (en) * | 1977-01-14 | 1979-11-20 | Pfizer Inc. | 2-Amino-3-cyano-4-hydroxyquinolines |
| US4247699A (en) | 1979-03-14 | 1981-01-27 | Pfizer Inc. | Process for making 2-amino-4-hydroxyquinolines |
| GB8727737D0 (en) * | 1987-11-26 | 1987-12-31 | Ici Plc | Antitumour agents |
| JPH11209350A (ja) * | 1998-01-26 | 1999-08-03 | Eisai Co Ltd | 含窒素複素環誘導体およびその医薬 |
| CA2356215C (en) | 1998-12-23 | 2015-11-24 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| CN100376557C (zh) | 2001-05-21 | 2008-03-26 | 霍夫曼-拉罗奇有限公司 | 作为神经肽y受体的配体的喹啉衍生物 |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US6818772B2 (en) | 2002-02-22 | 2004-11-16 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| MXPA05000081A (es) * | 2002-06-27 | 2005-04-11 | Schering Ag | Quinolinas sustituidas antagonistas del receptor ccr5. |
| CA2744997A1 (en) * | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| RS54271B1 (sr) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| US8686002B2 (en) | 2005-08-21 | 2014-04-01 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as binding partners for 5-HT5 receptors |
| CA2636043A1 (en) * | 2006-01-23 | 2007-08-02 | Amira Pharmaceuticals, Inc. | Tricyclic inhibitors of 5-lipoxygenase |
| WO2007092854A2 (en) | 2006-02-06 | 2007-08-16 | Janssen Pharmaceutica N.V. | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) |
| AR065093A1 (es) | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| US8076358B2 (en) | 2008-01-28 | 2011-12-13 | Janssen Pharmaceutica Nv | 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
| JP2011510993A (ja) | 2008-01-29 | 2011-04-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | β−セクレターゼ（ＢＡＣＥ）阻害剤として有用な２−アミノ−キノリン誘導体 |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| ES2598358T3 (es) * | 2009-02-13 | 2017-01-27 | Ucb Pharma, S.A. | Derivados de quinolina como inhibidores de PI3K quinasa |
| US9296698B2 (en) * | 2009-11-23 | 2016-03-29 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| US8822485B2 (en) | 2009-11-23 | 2014-09-02 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| US8735384B2 (en) | 2010-01-19 | 2014-05-27 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| WO2012037108A1 (en) * | 2010-09-13 | 2012-03-22 | Glaxosmithkline Llc | Aminoquinoline derivatives as antiviral agents |
| WO2012061557A2 (en) * | 2010-11-05 | 2012-05-10 | Glaxosmithkline Llc | Chemical compounds |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR102410078B1 (ko) | 2012-05-31 | 2022-06-22 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| DK2996473T3 (da) | 2013-05-18 | 2019-11-04 | Aduro Biotech Inc | Sammensætninger og fremgangsmåder til aktivering af "stimulator af interferon-gen"-afhængig signalering |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| SG11201601844TA (en) | 2013-09-13 | 2016-04-28 | Beigene Ltd | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| US9873670B2 (en) * | 2013-11-22 | 2018-01-23 | University Of Kentucky Research Foundation | Arylquinoline and analog compounds and use thereof to treat cancer |
| SG11201604738TA (en) | 2013-12-12 | 2016-07-28 | Shanghai Hengrui Pharm Co Ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| PT3578547T (pt) | 2015-02-16 | 2021-06-22 | The Provost Fellows Found Scholars And Other Members Of Board Of College Of Holy And Undivided Trini | Sulfonilureias e compostos relacionados e uso dos mesmos |
| CA2978942A1 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| US20160332971A1 (en) * | 2015-05-15 | 2016-11-17 | University Of Kentucky Research Foundation | Arylquinoline, arylquinolone and arylthioquinolone derivatives and use thereof to treat cancer |
| HUE050750T2 (hu) | 2015-05-29 | 2021-01-28 | Agenus Inc | CTLA-4 elleni antitestek és eljárások alkalmazásukra |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017027768A1 (en) * | 2015-08-13 | 2017-02-16 | The Broad Institute, Inc. | Compositions and methods for treating tuberculosis |
| US11130736B2 (en) * | 2015-08-21 | 2021-09-28 | University Of Kansas | Human TLR8-selective agonists |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| WO2017040670A1 (en) | 2015-09-01 | 2017-03-09 | Ifm Therapeutics, Inc | Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| CN111491362B (zh) | 2016-02-02 | 2023-10-24 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017184735A1 (en) | 2016-04-19 | 2017-10-26 | Ifm Therapeutics, Inc | Nlrp3 modulators |
| KR20180134395A (ko) | 2016-04-19 | 2018-12-18 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| CN106478621B (zh) * | 2016-09-30 | 2018-12-25 | 遵义医学院 | 喹啉或喹唑啉类衍生物、制备方法及其应用 |
| EP3555070B1 (en) * | 2016-12-19 | 2023-08-09 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| US20220056043A1 (en) * | 2019-02-19 | 2022-02-24 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof |
-
2018
- 2018-07-12 WO PCT/US2018/041723 patent/WO2019014402A1/en not_active Ceased
- 2018-07-12 SG SG11202000248UA patent/SG11202000248UA/en unknown
- 2018-07-12 CN CN201880046886.XA patent/CN110914258A/zh active Pending
- 2018-07-12 MY MYPI2020000168A patent/MY201080A/en unknown
- 2018-07-12 BR BR112020000523-1A patent/BR112020000523A2/pt not_active Application Discontinuation
- 2018-07-12 US US16/629,980 patent/US11344543B2/en active Active
- 2018-07-12 NZ NZ761519A patent/NZ761519A/en unknown
- 2018-07-12 CA CA3069524A patent/CA3069524A1/en active Pending
- 2018-07-12 PE PE2020000051A patent/PE20200296A1/es unknown
- 2018-07-12 JP JP2020501154A patent/JP7159282B2/ja active Active
- 2018-07-12 ES ES18746537T patent/ES3002968T3/es active Active
- 2018-07-12 EP EP18746537.2A patent/EP3652166B1/en active Active
- 2018-07-12 AU AU2018301681A patent/AU2018301681B2/en not_active Ceased
- 2018-07-12 KR KR1020207003984A patent/KR102698385B1/ko active Active
- 2018-07-12 CN CN202010596091.5A patent/CN111793060B/zh active Active
- 2018-07-13 TW TW107124243A patent/TWI791556B/zh not_active IP Right Cessation
-
2020
- 2020-01-09 IL IL271935A patent/IL271935A/en unknown
- 2020-01-10 CO CONC2020/0000227A patent/CO2020000227A2/es unknown
- 2020-01-10 CL CL2020000085A patent/CL2020000085A1/es unknown
-
2022
- 2022-04-28 US US17/731,279 patent/US12171756B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020000085A1 (es) | 2020-07-10 |
| TWI791556B (zh) | 2023-02-11 |
| CN110914258A (zh) | 2020-03-24 |
| JP2020527139A (ja) | 2020-09-03 |
| MY201080A (en) | 2024-02-03 |
| TW201908304A (zh) | 2019-03-01 |
| PE20200296A1 (es) | 2020-02-06 |
| CA3069524A1 (en) | 2019-01-17 |
| SG11202000248UA (en) | 2020-02-27 |
| BR112020000523A2 (pt) | 2020-07-14 |
| CN111793060B (zh) | 2023-06-06 |
| CN111793060A (zh) | 2020-10-20 |
| US20200129500A1 (en) | 2020-04-30 |
| US20220257587A1 (en) | 2022-08-18 |
| EP3652166A1 (en) | 2020-05-20 |
| KR20200028434A (ko) | 2020-03-16 |
| WO2019014402A1 (en) | 2019-01-17 |
| AU2018301681A1 (en) | 2020-02-27 |
| AU2018301681B2 (en) | 2022-07-14 |
| EP3652166B1 (en) | 2024-11-20 |
| KR102698385B1 (ko) | 2024-08-22 |
| NZ761519A (en) | 2023-07-28 |
| JP7159282B2 (ja) | 2022-10-24 |
| US12171756B2 (en) | 2024-12-24 |
| US11344543B2 (en) | 2022-05-31 |
| ES3002968T3 (en) | 2025-03-10 |
| IL271935A (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021006672A2 (es) | Moduladores de nlrp3 | |
| CO2020000227A2 (es) | Moduladores de nlrp3 | |
| CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
| MX2020001360A (es) | Macrociclos de diarilo como moduladores de la proteina quinasa. | |
| CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
| CO2019013016A2 (es) | Inhibidores pirazólicos de magl | |
| CO2017005959A2 (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| ECSP16073190A (es) | Ciclopropilaminas como inhibidores de lsd1 | |
| UY36077A (es) | Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen | |
| CL2018001569A1 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| CO2021014008A2 (es) | Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
| MX389724B (es) | Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
| ECSP16074207A (es) | Pirazinas moduladoras de gpr6 | |
| CL2020001093A1 (es) | Proceso para preparar el benzotiofen-2-il boronato. | |
| AR107460A1 (es) | Gabapentina oftálmica para el tratamiento de las úlceras corneales | |
| ECSP16094286A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
| DOP2017000196A (es) | Derivados de tetrahidropiranil benzamida | |
| MX2019003311A (es) | Metodos para tratamiento de cancer de ovario. | |
| EA202090283A1 (ru) | Модуляторы nlrp3 | |
| EA202092539A1 (ru) | Модуляторы nlrp3 | |
| MX2020004871A (es) | Derivados de acido cafeico y sus usos. |